Successes and Challenges of PARP Inhibitors in Cancer Therapy

Overview

Journal Front Oncol

Specialty Oncology

Date 2015 Nov 4

PMID 26528434

Citations 35

Authors

Tiffany K Ricks

Haw-Jyh Chiu

Gwynn Ison

Geoffrey Kim

Amy E McKee

Paul Kluetz

Richard Pazdur

Affiliations

Soon will be listed here.

Citing Articles

Olaparib increases chemosensitivity by upregulating miR-125a-3p in ovarian cancer cells.

Wang Z, Pu T, Miao W, Gao Y, Gao J, Zhang X Discov Oncol. 2025; 16(1):291.

PMID: 40064834 PMC: 11893969. DOI: 10.1007/s12672-025-02048-7.

Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization.

Zhang Y, Liang L, Li Z, Huang Y, Jiang M, Zou B Front Oncol. 2023; 13:1295579.

PMID: 38111536 PMC: 10726039. DOI: 10.3389/fonc.2023.1295579.

Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.

Mirsya Warli S, Velaro A, Firsty N, Tala Z World J Oncol. 2023; 14(6):518-528.

PMID: 38022404 PMC: 10681786. DOI: 10.14740/wjon1685.

Clinical prospects of WRN inhibition as a treatment for MSI tumours.

Morales-Juarez D, Jackson S NPJ Precis Oncol. 2022; 6(1):85.

PMID: 36379964 PMC: 9666358. DOI: 10.1038/s41698-022-00319-y.

Toxicological Properties of 7-Methylguanine, and Preliminary Data on its Anticancer Activity.

Kirsanov K, Fetisov T, Antoshina E, Trukhanova L, Gorkova T, Vlasova O Front Pharmacol. 2022; 13:842316.

PMID: 35873588 PMC: 9299380. DOI: 10.3389/fphar.2022.842316.

References

Barber L, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K . Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol. 2012; 229(3):422-9. DOI: 10.1002/path.4140. View

Murai J, Huang S, Das B, Renaud A, Zhang Y, Doroshow J . Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72(21):5588-99. PMC: 3528345. DOI: 10.1158/0008-5472.CAN-12-2753. View

Curtin N, Szabo C . Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med. 2013; 34(6):1217-56. PMC: 3657315. DOI: 10.1016/j.mam.2013.01.006. View

Smith M, Reynolds C, Kang M, Kolb E, Gorlick R, Carol H . Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res. 2014; 21(4):819-32. PMC: 4587665. DOI: 10.1158/1078-0432.CCR-14-2572. View

Hopkins T, Shi Y, Rodriguez L, Solomon L, Donawho C, DiGiammarino E . Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors. Mol Cancer Res. 2015; 13(11):1465-77. DOI: 10.1158/1541-7786.MCR-15-0191-T. View

Ji J, Kinders R, Zhang Y, Rubinstein L, Kummar S, Parchment R . Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells. PLoS One. 2011; 6(10):e26152. PMC: 3189959. DOI: 10.1371/journal.pone.0026152. View

De Lorenzo S, Patel A, Hurley R, Kaufmann S . The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. Front Oncol. 2013; 3:228. PMC: 3769628. DOI: 10.3389/fonc.2013.00228. View

McCabe N, Turner N, Lord C, Kluzek K, Bialkowska A, Swift S . Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006; 66(16):8109-15. DOI: 10.1158/0008-5472.CAN-06-0140. View

Lowndes N, Toh G . DNA repair: the importance of phosphorylating histone H2AX. Curr Biol. 2005; 15(3):R99-R102. DOI: 10.1016/j.cub.2005.01.029. View

10.

Gibson B, Kraus W . New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012; 13(7):411-24. DOI: 10.1038/nrm3376. View

11.

Wang M, Wu W, Wu W, Rosidi B, Zhang L, Wang H . PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006; 34(21):6170-82. PMC: 1693894. DOI: 10.1093/nar/gkl840. View

12.

Bryant H, Schultz N, Thomas H, Parker K, Flower D, Lopez E . Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035):913-7. DOI: 10.1038/nature03443. View

13.

Meyer S, Tischkowitz M, Chandler K, Gillespie A, Birch J, Evans D . Fanconi anaemia, BRCA2 mutations and childhood cancer: a developmental perspective from clinical and epidemiological observations with implications for genetic counselling. J Med Genet. 2013; 51(2):71-5. DOI: 10.1136/jmedgenet-2013-101642. View

14.

Fong P, Boss D, Yap T, Tutt A, Wu P, Mergui-Roelvink M . Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361(2):123-34. DOI: 10.1056/NEJMoa0900212. View

15.

Kummar S, Kinders R, Gutierrez M, Rubinstein L, Parchment R, Phillips L . Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009; 27(16):2705-11. PMC: 2739635. DOI: 10.1200/JCO.2008.19.7681. View

16.

Tutt A, Robson M, Garber J, Domchek S, Audeh M, Weitzel J . Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376(9737):235-44. DOI: 10.1016/S0140-6736(10)60892-6. View

17.

Rogakou E, Pilch D, Orr A, Ivanova V, Bonner W . DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998; 273(10):5858-68. DOI: 10.1074/jbc.273.10.5858. View

18.

Murai J, Huang S, Renaud A, Zhang Y, Ji J, Takeda S . Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2013; 13(2):433-43. PMC: 3946062. DOI: 10.1158/1535-7163.MCT-13-0803. View

19.

Rouleau M, Patel A, Hendzel M, Kaufmann S, Poirier G . PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010; 10(4):293-301. PMC: 2910902. DOI: 10.1038/nrc2812. View

20.

Galande S, Kohwi-Shigematsu T . Poly(ADP-ribose) polymerase and Ku autoantigen form a complex and synergistically bind to matrix attachment sequences. J Biol Chem. 1999; 274(29):20521-8. DOI: 10.1074/jbc.274.29.20521. View